Maria Marples
YOU?
Author Swipe
View article: O09 From skin to gut: the journey of metastatic melanoma in the gastrointestinal tract
O09 From skin to gut: the journey of metastatic melanoma in the gastrointestinal tract Open
Melanoma is the most common solid tumour that can spread to the gastrointestinal tract (GIT), although the GIT remains a less common site for melanoma metastases. Melanoma GIT metastases can present with vague symptoms and may emerge years…
View article: Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata Open
Background Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. Methods Axi-STS was a pathologically-stratified, non-randomised, open-label, multi-cen…
View article: Supplementary Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma
Supplementary Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma Open
Supplementary Figure S1, Supplementary Methods, and Supplementary Tables S1-S2.
View article: Supplementary Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma
Supplementary Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma Open
Supplementary Figure S1, Supplementary Methods, and Supplementary Tables S1-S2.
View article: Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma
Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma Open
Purpose: To use gene expression profiling of formalin-fixed primary melanoma samples to detect expression patterns that are predictive of relapse and response to chemotherapy.Experimental Design: Gene expression profiles were identified in…
View article: Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma
Data from Patterns of Expression of DNA Repair Genes and Relapse From Melanoma Open
Purpose: To use gene expression profiling of formalin-fixed primary melanoma samples to detect expression patterns that are predictive of relapse and response to chemotherapy.Experimental Design: Gene expression profiles were identified in…
View article: Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review
Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review Open
The differential diagnosis of non-coeliac enteropathies (NCEs) is challenging and includes a wide range of aetiologies. Drug-induced NCEs are relatively common and characterized by duodenal villous atrophy, which resolves upon suspension o…
View article: Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy
Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy Open
Dacarbazine chemotherapy has been the mainstay of melanoma treatment for >30 years. In the early 2000s, carboplatin (with or without other agents, such as paclitaxel) was the most commonly used second-line therapy in the UK. The aim of the…
View article: MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe
MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe Open
Introduction Immune checkpoint inhibitors (ICIs) are immunomodulatory molecules that downregulate T-cell inhibiting-receptors or ligands to promote an enhanced anti-tumour response. Ipilimumab is a human monoclonal antibody directed agains…
View article: Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial Open
Ann Oncol 2018; 29(8): 1843–1852 (doi: 10.1093/annonc/mdy229) In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article. Adjuvant bevacizumab for melanoma patie…
View article: Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study Open
This study provides important new data on biomarkers in early-stage melanoma, which contrast with biomarker profiles in advanced disease. These biomarkers may represent the host inflammatory response to melanoma and therefore could help se…
View article: Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Open
Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.
View article: Ipilimumab-induced colitis: experience from a tertiary referral center
Ipilimumab-induced colitis: experience from a tertiary referral center Open
Background: Ipilimumab is an anticytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody used for the treatment of malignant melanoma. It can cause immune-mediated inflammatory adverse events, including diarrhoea and even intestinal …
View article: Ipilimumab in the real world
Ipilimumab in the real world Open
Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. …